keyword
MENU ▼
Read by QxMD icon Read
search

adverse reactions corticosteroid injections

keyword
https://www.readbyqxmd.com/read/29563108/phase-iii-trial-results-with-blisibimod-a-selective-inhibitor-of-b-cell-activating-factor-in-subjects-with-systemic-lupus-erythematosus-sle-results-from-a-randomised-double-blind-placebo-controlled-trial
#1
Joan T Merrill, William R Shanahan, Morton Scheinberg, Kenneth C Kalunian, David Wofsy, Renee S Martin
BACKGROUND: Targeted inhibitors of B-cell activating factor (BAFF) have been evaluated in phase III trials in over 4000 patients with systemic lupus erythematosus (SLE). Post hoc analyses of these studies identify greater treatment effect in patients entering with higher disease activity, greater corticosteroid doses, anti double-stranded DNA (dsDNA) and low complement C3 or C4. OBJECTIVES: To evaluate the efficacy and safety of blisibimod, a BAFF inhibitor, in a population of patients with SLE enriched for high disease activity...
March 21, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29503598/dupilumab-an-evidence-based-review-of-its-potential-in-the-treatment-of-atopic-dermatitis
#2
REVIEW
Panteha Eshtiaghi, Melinda J Gooderham
Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with complex immunopathogenesis characterized by a dominant TH 2 response. Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that subsequently blocks IL-4 and IL-13 signaling. It has recently been approved for the treatment of adult patients with moderate-to-severe AD whose current treatment options are limited. Aim: This article reviews the evidence of clinical efficacy, safety, and patient-reported out-come (PRO) measures from Phase I-III trials of dupilumab in adult patients with moderate-to-severe AD...
2018: Core Evidence
https://www.readbyqxmd.com/read/29471919/dupilumab-a-review-of-its-use-in-the-treatment-of-atopic-dermatitis
#3
Melinda J Gooderham, H Chih-Ho Hong, Panteha Eshtiaghi, Kim A Papp
Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD...
March 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29466690/safety-and-efficacy-of-etanercept-methotrexate-combination-therapy-in-patients-with-rhupus-an-observational-study-of-non-glucocorticoid-treatment-for-rheumatic-diseases
#4
Bei-Bei Yang, Hua Xiao, Xiao-Jie Li, Min Zheng
OBJECTIVES: To evaluate the safety and efficacy of etanercept (ETN) plus methotrexate (MTX) in patients with rhupus without using corticosteroids. METHODS: Twenty rhupus patients [meeting the criteria for both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)] who had never been treated with corticosteroids, DMARDs, or biological agents with a 28-joint Disease Activity Score (DAS28) >3.2 and lupus nephritis determined from histopathological specimens were enrolled...
January 2018: Discovery Medicine
https://www.readbyqxmd.com/read/29315479/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and-concomitant-topical-corticosteroids-liberty-ad-chronos-a-critical-appraisal
#5
J Thomson, A G H Wernham, H C Williams
AIM: Blauvelt et al. aimed to compare the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) vs. placebo with TCS in adults with moderate-to-severe atopic dermatitis (AD). SETTING AND DESIGN: This multicentre randomized, double-blinded, placebo-controlled trial was conducted in hospitals, clinics and academic institutions across 161 sites in 14 countries. STUDY EXPOSURE: Adults with moderate-to-severe AD were randomly assigned (3: 1: 3) to receive subcutaneous dupilumab 300 mg once weekly plus TCS, dupilumab 300 mg every 2 weeks plus TCS or placebo plus TCS until week 52...
January 6, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29151132/safety-of-intrathecal-route-focus-to-methylprednisolone-acetate-depo-medrol-use
#6
REVIEW
Joël Schlatter, David Nguyen, Michèle Zamy, Sofiane Kabiche, Jean-Eudes Fontan, Salvatore Cisternino
PURPOSE: Complications of the intrathecal route may cause potential toxicity related to the medical device and properties of the administered drug and/or excipient. A description of clinical and histological effects of polyethylene glycol and miripirium after Depo-Medrol injection, and the adverse reactions of particulate methylprednisolone acetate was conducted. The safety of the intrathecal route with excipients, label and off-label drugs is discussed. METHODS: A bibliographic search in Medline, Google, and Cochrane database from 1940 to June 2016 was performed...
November 18, 2017: European Spine Journal
https://www.readbyqxmd.com/read/28478972/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and-concomitant-topical-corticosteroids-liberty-ad-chronos-a-1-year-randomised-double-blinded-placebo-controlled-phase-3-trial
#7
RANDOMIZED CONTROLLED TRIAL
Andrew Blauvelt, Marjolein de Bruin-Weller, Melinda Gooderham, Jennifer C Cather, Jamie Weisman, David Pariser, Eric L Simpson, Kim A Papp, H Chih-Ho Hong, Diana Rubel, Peter Foley, Errol Prens, Christopher E M Griffiths, Takafumi Etoh, Pedro Herranz Pinto, Ramon M Pujol, Jacek C Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M H Graham, Gianluca Pirozzi, Neil Stahl, George D Yancopoulos, Brad Shumel
BACKGROUND: Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis...
June 10, 2017: Lancet
https://www.readbyqxmd.com/read/28394710/blood-glucose-levels-after-local-musculoskeletal-steroid-injections-in-patients-with-diabetes-mellitus-a-clinical-review
#8
REVIEW
Anna L Waterbrook, Brenden J Balcik, Aaron John Goshinska
CONTEXT: Diabetes mellitus (DM) has become an epidemic in the United States and is associated with increased risk of multiple comorbidities, including painful musculoskeletal conditions. A common treatment for many of these painful musculoskeletal conditions is local soft tissue and intra-articular corticosteroid injection (CSI). These local injections have the potential to cause elevated blood glucose levels (BGLs) and cause complications in patients with DM. Therefore, it was the objective of this investigation to review the currently available evidence that directly addresses the effects of local CSIs used for painful musculoskeletal conditions on BGL in patients with DM...
July 2017: Sports Health
https://www.readbyqxmd.com/read/28326908/sublingual-immunotherapy-tablets-as-a-disease-modifying-add-on-treatment-option-to-pharmacotherapy-for-allergic-rhinitis-and-asthma
#9
REVIEW
Stephen Brunton, Harold S Nelson, David I Bernstein, Simon Lawton, Susan Lu, Hendrik Nolte
Allergic rhinitis (AR) with or without conjunctivitis (AR/C) is associated with a significant health and economic burden, and is often accompanied by asthma. Pharmacotherapies are the mainstay treatment options for AR and asthma, but guidelines also recommend allergy immunotherapy (AIT). Unlike pharmacotherapies, AIT has the ability to modify the underlying immunologic mechanisms of AR and asthma with the potential for long-term benefits after treatment is discontinued. Immunotherapy may also prevent progression of AR/C to asthma...
August 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28152754/eleven-year-experience-with-a-web-based-medication-occurrence-mo-reporting-tool-in-a-community-oncology-practice
#10
Tae W Jang, Jim R Schwartz
53 Background: At ASCO 2007, we presented 2 year experience with a web-based Medication Occurrence (MO) reporting tool. We now report the 11 year experience in a single outpatient oncology practice. METHODS: Since December 2003, Texas Oncology (TxO) sites have entered information on Medication Occurrence (MO) reports in an electronic Variance Reporting tool. The pharmacy management team generates reports monthly for the Texas Oncology Quality Oversight Committee and each site Quality Committee for analysis and follow-up action...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28124198/laser-assisted-topical-corticosteroid-delivery-for-the-treatment-of-keloids
#11
Ji Hye Park, Ji Young Chun, Jong Hee Lee
Laser-assisted drug delivery has generated intense interest. The objectives of this study are to evaluate the clinical benefit of laser-assisted corticosteroid delivery and to compare this technique to corticosteroid intralesional injection, a standard treatment for keloids. Patients with keloids on the left shoulder after BCG vaccination were enrolled in this study. The entire lesion was first treated with an ablative fractional erbium-YAG laser. After this treatment, the lesion was divided into two halves...
April 2017: Lasers in Medical Science
https://www.readbyqxmd.com/read/28116937/the-safety-of-mepolizumab-for-the-treatment-of-asthma
#12
REVIEW
E Leung, K Al Efraij, J M FitzGerald
Asthma is an airway disease characterized by airway inflammation. It is associated with significant morbidity, mortality, and costs to the healthcare system and society. Interleukin-5 (IL-5) was identified for its role in eosinophil development, maturation, and survival in tissues, which has been related to disease severity and airway eosinophilia. Areas covered: In this review, we will present the pharmacokinetics and dynamics of mepolizumab in addition to efficacy and safety data. Expert Opinion: Mepolizumab is novel, new, first-in-class therapy targeting IL-5...
March 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27777060/adverse-reaction-to-hyaluronic-acid-injection-laryngoplasty-a-case-report
#13
Henri Traboulsi, Tamer El Natout, Ghassan Skaff, Abdul-Latif Hamdan
INTRODUCTION: Injection laryngoplasty using hyaluronic acid is a safe procedure commonly performed on patients with glottic insufficiency. STUDY DESIGN: This is a descriptive study of a case of adverse reaction to hyaluronic acid in a patient who underwent injection laryngoplasty for the treatment of unilateral vocal cord paralysis. DISCUSSION: The patient was treated with antibiotics and corticosteroids and had a full recovery. The authors recommend close observation following injection laryngoplasty using hyaluronic acid and diligent investigation of persistent postoperative laryngopharyngeal symptoms...
March 2017: Journal of Voice: Official Journal of the Voice Foundation
https://www.readbyqxmd.com/read/27739370/systemic-allergy-to-corticosteroids-clinical-features-and-cross-reactivity
#14
REVIEW
Annick Barbaud, Julie Waton
Systemic hypersensitivity (HS) to corticosteroids (CS) is paradoxical but does exist. Some patients with a previous contact allergy to topical CS may develop a systemic contact dermatitis (SCD) while receiving CS orally or intravenously. However, a previous contact sensitization is not mandatory for developing a systemic HS to CS. Acute or delayed urticaria can occur in immediate HS. Immediate HS can be due to excipients, mainly carboxymethylcellulose or to CS themselves. Delayed reactions, mainly maculopapular rash and acute generalized exanthematous pustulosis can occur...
2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27229691/-extended-abstractcutaneous-adverse-reactions-to-tattoos
#15
S A S van der Bent, A Wolkerstorfer, T Rustemeyer
INTRODUCTION: Tattooing involves the introduction of exogenous pigment into the dermis. Worldwide, tattoos are one of the most popular forms of permanent body art. In the Netherlands, 8-10% of the population older than 12 years old has a tattoo. A wide variety of cutaneous adverse effects can occur in tattoos, these can cause serious symptoms. However, recognition and appropriate knowledge of diagnosis and treatment is still frequently insufficient in many medical practitioners. CASE DESCRIPTION: The first case concerns a 57-year-old female, who developed an itching swelling in the red part of a tattoo on the left arm...
2016: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/27130691/dupilumab-efficacy-and-safety-in-adults-with-uncontrolled-persistent-asthma-despite-use-of-medium-to-high-dose-inhaled-corticosteroids-plus-a-long-acting-%C3%AE-2-agonist-a-randomised-double-blind-placebo-controlled-pivotal-phase-2b-dose-ranging-trial
#16
RANDOMIZED CONTROLLED TRIAL
Sally Wenzel, Mario Castro, Jonathan Corren, Jorge Maspero, Lin Wang, Bingzhi Zhang, Gianluca Pirozzi, E Rand Sutherland, Robert R Evans, Vijay N Joish, Laurent Eckert, Neil M H Graham, Neil Stahl, George D Yancopoulos, Mariana Louis-Tisserand, Ariel Teper
BACKGROUND: Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist, irrespective of baseline eosinophil count...
July 2, 2016: Lancet
https://www.readbyqxmd.com/read/26958534/clinical-evidence-in-the-treatment-of-rotator-cuff-tears-with-hyaluronic-acid
#17
REVIEW
Leonardo Osti, Matteo Buda, Angelo Del Buono, Raffaella Osti, Leo Massari
PURPOSE: the aim of this quantitative review is to document potential benefit and adverse effects of hyaluronic acid (HA) injection into the shoulder with rotator cuff tears. METHODS: a systematic literature search was performed in english PubMed, Medline, Ovid, Google Scholar and Embase databases using the combined key words "hyaluronic acid", "rotator cuff tear", "hyaluronate", "shoulder", "viscosupplementation", with no limit regarding the year of publication...
October 2015: Muscles, Ligaments and Tendons Journal
https://www.readbyqxmd.com/read/26941199/paclitaxel-injection-concentrate-for-nanodispersion-versus-nab-paclitaxel-in-women-with-metastatic-breast-cancer-a-multicenter-randomized-comparative-phase-ii-iii-study
#18
RANDOMIZED CONTROLLED TRIAL
Minish M Jain, Smita U Gupte, Shekhar G Patil, Anand B Pathak, Chetan D Deshmukh, Niraj Bhatt, Chiramana Haritha, K Govind Babu, Shailesh A Bondarde, Raghunadharao Digumarti, Jyoti Bajpai, Ravi Kumar, Ashish V Bakshi, Gouri Sankar Bhattacharya, Poonam Patil, Sundaram Subramanian, Ashok K Vaid, Chirag J Desai, Ajay Khopade, Geetanjali Chimote, Poonamalle P Bapsy, Shravanti Bhowmik
Paclitaxel is widely used in the treatment of patients with metastatic breast cancer (MBC). Formulations of paclitaxel contain surfactants and solvents or albumin derived from human blood. The use of co-solvents such as polyoxyethylated castor oil is thought to contribute to toxicity profile and hypersensitivity reactions as well as leaching of plasticizers from polyvinyl chloride bags and infusion sets. Currently, nab-paclitaxel, an albumin-bound paclitaxel in nanometer range continues to be the preferred taxane formulation used in clinic...
February 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/26940554/azacitidine-induced-pericarditis-a-case-series
#19
Matthew Newman, Midhun Malla, Ivana Gojo
STUDY OBJECTIVE: To describe three cases of pericarditis probably related to azacitidine administration in a span of 3 years at our center. DESIGN: Case series. SETTING: Comprehensive cancer center within a large, academic medical center. PATIENTS: Three patients with high-grade myelodysplastic syndrome or acute myeloid leukemia who received azacitidine. INTERVENTION: None. MEASUREMENTS: None...
April 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/26836729/effect-of-subcutaneous-dupilumab-on-nasal-polyp-burden-in-patients-with-chronic-sinusitis-and-nasal-polyposis-a-randomized-clinical-trial
#20
RANDOMIZED CONTROLLED TRIAL
Claus Bachert, Leda Mannent, Robert M Naclerio, Joaquim Mullol, Berrylin J Ferguson, Philippe Gevaert, Peter Hellings, Lixia Jiao, Lin Wang, Robert R Evans, Gianluca Pirozzi, Neil M Graham, Brian Swanson, Jennifer D Hamilton, Allen Radin, Namita A Gandhi, Neil Stahl, George D Yancopoulos, E Rand Sutherland
IMPORTANCE: Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both type 2 helper T-cell-mediated diseases. OBJECTIVE: To assess inhibition of interleukins 4 and 13 with dupilumab in patients with chronic sinusitis and nasal polyposis. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled parallel-group study conducted at 13 sites in the United States and Europe between August 2013 and August 2014 in 60 adults with chronic sinusitis and nasal polyposis refractory to intranasal corticosteroids with 16 weeks of follow-up...
February 2, 2016: JAMA: the Journal of the American Medical Association
keyword
keyword
76651
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"